Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer
NCT04148911Phase 3Completed
- Sponsor
- Roche
- Start
- Dec 2019
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies
- Countries
- 13
01
Overview
Phase 3, open-label, single-arm trial of atezolizumab in triple-negative breast cancer (TNBC), sponsored by Roche. Primary endpoints: Treatment-emergent Grade ≥3 Adverse Events at 60 months and Treatment-emergent Grade ≥2 Immune-mediated Adverse Events at 60 months. Started Dec 2019; status: completed.
02
Drugs
atezolizumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT04148911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04148911.